Dianthus Therapeutics News and Activities
Presence
Dianthus Therapeutics is a biotechnology company that develops antibody medicines for severe autoimmune diseases. Its main services include drug research and clinical development for patients, doctors, and healthcare systems.
Dianthus Therapeutics products and services overview:
- Antibody therapies
- Autoimmune treatments
- Drug research
- Clinical development
Revenue: ~$0 million
Employees: 80
Headquarters: Waltham, United States (USA)
Dianthus Therapeutics is one of the...
Dianthus Therapeutics is a company listed under the stock ticker DNTH (US).
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Dianthus Therapeutics
- Marino Garcia, Director, President and Chief Executive Officer
- Sujay Kango, Director
- Steven Romano, Director
Create your alert
to follow the executive moves at Dianthus Therapeutics.
Biotechnology
Dianthus Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Investor Relations | Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Scientific Publications | Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Investor Relations | Dianthus Therapeutics
- Home - Dianthus Therapeutics
- View more press releases Close
Social media about Dianthus Therapeutics
- Dianthus Therapeutics on Wikipedia, Google News & Yahoo Finance
- Dianthus Therapeutics on LinkedIn, X (Twitter) & YouTube
